Sellas Life Sciences Stock Price To Sales

SLS Stock

USD 1.21 0.13 12.04%

Sellas Life Sciences fundamentals help investors to digest information that contributes to Sellas Life's financial success or failures. It also enables traders to predict the movement of Sellas Stock. The fundamental analysis module provides a way to measure Sellas Life's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Sellas Life stock.

		Last Reported	Projected for Next Year
	Price To Sales Ratio	52.64	60.05

Price To Sales Ratio is likely to gain to 60.05 in 2025.

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Sellas Life Sciences Company Price To Sales Analysis

Sellas Life's Price to Sales ratio is typically used for valuing equity relative to its own past performance as well as to performance of other companies or market indexes. In most cases, the lower the ratio, the better it is for investors. However, it is advisable for investors to exercise caution when looking at price-to-sales ratios across different industries.

P/S

MV Per Share

Revenue Per Share

More About Price To Sales | All Equity Analysis

Current Sellas Life Price To Sales

26.90 X

Most of Sellas Life's fundamental indicators, such as Price To Sales, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Sellas Life Sciences is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Sellas Price To Sales Driver Correlations

Understanding the fundamental principles of building solid financial models for Sellas Life is extremely important. It helps to project a fair market value of Sellas Stock properly, considering its historical fundamentals such as Price To Sales. Since Sellas Life's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Sellas Life's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Sellas Life's interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Net Debt	Total Current Assets	Retained Earnings	Accounts Payable	Short Term Investments	Total Liab	Common Stock	Current Deferred Revenue	Short Term Debt	Net Tangible Assets	Good Will	Long Term Debt Total	Capital Surpluse	Intangible Assets	Property Plant Equipment	Long Term Debt	Deferred Long Term Liab	Net Receivables	Short Long Term Debt	Net Invested Capital	Net Working Capital	Capital Stock
Total Assets		0.68	-0.63	0.93	-0.45	-0.23	-0.3	0.86	0.82	0.66	0.46	0.06	0.63	0.63	0.71	0.79	-0.35	0.6	0.47	0.46	-0.05	0.53	-0.13	-0.32
Total Stockholder Equity	0.68		-0.52	0.64	-0.16	-0.33	-0.11	0.22	0.5	0.28	0.34	0.68	0.44	0.1	0.52	0.53	-0.43	0.04	0.21	0.09	-0.07	0.75	0.3	-0.34
Net Debt	-0.63	-0.52		-0.78	0.12	0.32	0.15	-0.47	-0.3	-0.3	0.27	-0.29	-0.3	-0.24	-0.28	-0.2	-0.09	-0.24	-0.23	-0.34	0.35	-0.55	-0.37	0.32
Total Current Assets	0.93	0.64	-0.78		-0.45	-0.27	-0.29	0.8	0.71	0.61	0.36	0.09	0.52	0.6	0.69	0.54	-0.19	0.61	0.49	0.53	0.04	0.59	0.07	-0.37
Retained Earnings	-0.45	-0.16	0.12	-0.45		0.23	0.57	-0.51	-0.69	-0.51	-0.47	-0.11	-0.16	-0.72	-0.87	-0.3	-0.28	-0.74	-0.03	-0.32	-0.61	0.26	0.2	0.03
Accounts Payable	-0.23	-0.33	0.32	-0.27	0.23		-0.37	-0.1	-0.44	-0.21	0.03	-0.42	-0.6	-0.11	-0.46	-0.21	-0.04	-0.18	-0.42	-0.3	0.05	-0.22	-0.02	0.11
Short Term Investments	-0.3	-0.11	0.15	-0.29	0.57	-0.37		-0.33	-0.23	-0.28	-0.23	0.06	0.41	-0.57	-0.33	-0.05	-0.19	-0.49	0.45	0.05	-0.46	0.15	-0.22	-0.1
Total Liab	0.86	0.22	-0.47	0.8	-0.51	-0.1	-0.33		0.75	0.68	0.38	-0.36	0.56	0.79	0.6	0.69	-0.15	0.8	0.48	0.55	-0.01	0.17	-0.39	-0.22
Common Stock	0.82	0.5	-0.3	0.71	-0.69	-0.44	-0.23	0.75		0.67	0.58	0.11	0.73	0.62	0.88	0.71	-0.36	0.67	0.55	0.53	0.22	0.15	-0.43	-0.03
Current Deferred Revenue	0.66	0.28	-0.3	0.61	-0.51	-0.21	-0.28	0.68	0.67		0.24	-0.1	0.35	0.58	0.65	0.56	-0.2	0.8	0.2	0.82	0.15	0.19	-0.14	-0.07
Short Term Debt	0.46	0.34	0.27	0.36	-0.47	0.03	-0.23	0.38	0.58	0.24		-0.1	0.3	0.47	0.62	0.46	-0.42	0.39	0.38	0.05	0.61	0.19	-0.29	-0.15
Net Tangible Assets	0.06	0.68	-0.29	0.09	-0.11	-0.42	0.06	-0.36	0.11	-0.1	-0.1		0.11	-0.3	0.26	0.0	0.02	-0.31	-0.16	-0.16	-0.01	0.3	0.41	-0.16
Good Will	0.63	0.44	-0.3	0.52	-0.16	-0.6	0.41	0.56	0.73	0.35	0.3	0.11		0.16	0.48	0.7	-0.43	0.23	0.83	0.46	-0.3	0.31	-0.54	-0.27
Long Term Debt Total	0.63	0.1	-0.24	0.6	-0.72	-0.11	-0.57	0.79	0.62	0.58	0.47	-0.3	0.16		0.7	0.5	0.14	0.9	0.08	0.26	0.39	-0.01	-0.13	-0.05
Capital Surpluse	0.71	0.52	-0.28	0.69	-0.87	-0.46	-0.33	0.6	0.88	0.65	0.62	0.26	0.48	0.7		0.58	-0.05	0.72	0.31	0.44	0.47	0.15	-0.16	-0.16
Intangible Assets	0.79	0.53	-0.2	0.54	-0.3	-0.21	-0.05	0.69	0.71	0.56	0.46	0.0	0.7	0.5	0.58		-0.44	0.42	0.35	0.26	-0.24	0.31	-0.43	-0.22
Property Plant Equipment	-0.35	-0.43	-0.09	-0.19	-0.28	-0.04	-0.19	-0.15	-0.36	-0.2	-0.42	0.02	-0.43	0.14	-0.05	-0.44		0.11	-0.46	-0.15	0.14	-0.38	0.29	-0.12
Long Term Debt	0.6	0.04	-0.24	0.61	-0.74	-0.18	-0.49	0.8	0.67	0.8	0.39	-0.31	0.23	0.9	0.72	0.42	0.11		0.17	0.61	0.44	-0.04	-0.18	-0.08
Deferred Long Term Liab	0.47	0.21	-0.23	0.49	-0.03	-0.42	0.45	0.48	0.55	0.2	0.38	-0.16	0.83	0.08	0.31	0.35	-0.46	0.17		0.5	-0.1	0.33	-0.48	-0.23
Net Receivables	0.46	0.09	-0.34	0.53	-0.32	-0.3	0.05	0.55	0.53	0.82	0.05	-0.16	0.46	0.26	0.44	0.26	-0.15	0.61	0.5		0.04	0.16	-0.23	-0.14
Short Long Term Debt	-0.05	-0.07	0.35	0.04	-0.61	0.05	-0.46	-0.01	0.22	0.15	0.61	-0.01	-0.3	0.39	0.47	-0.24	0.14	0.44	-0.1	0.04		-0.21	0.09	0.06
Net Invested Capital	0.53	0.75	-0.55	0.59	0.26	-0.22	0.15	0.17	0.15	0.19	0.19	0.3	0.31	-0.01	0.15	0.31	-0.38	-0.04	0.33	0.16	-0.21		0.5	-0.45
Net Working Capital	-0.13	0.3	-0.37	0.07	0.2	-0.02	-0.22	-0.39	-0.43	-0.14	-0.29	0.41	-0.54	-0.13	-0.16	-0.43	0.29	-0.18	-0.48	-0.23	0.09	0.5		-0.11
Capital Stock	-0.32	-0.34	0.32	-0.37	0.03	0.11	-0.1	-0.22	-0.03	-0.07	-0.15	-0.16	-0.27	-0.05	-0.16	-0.22	-0.12	-0.08	-0.23	-0.14	0.06	-0.45	-0.11

Click cells to compare fundamentals

Sellas Price To Sales Historical Pattern

Today, most investors in Sellas Life Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Sellas Life's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's price to sales growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Sellas Life price to sales as a starting point in their analysis.

Sellas Life Price To Sales

Timeline

The most critical factor to remember is that the price of equity takes a firm's debt into account, whereas the sales indicators do not consider financial leverage. Generally speaking, Price to Sales ratio shows how much market values every dollar of the company's sales.

Competition

Predict Sellas Life

Price To Sales Ratio Over Time

Sellas Price To Sales Ratio

Price To Sales Ratio

60.05

At this time, Sellas Life's Price To Sales Ratio is comparatively stable compared to the past year.

Based on the latest financial disclosure, Sellas Life Sciences has a Price To Sales of 26.8951 times. This is 25.68% higher than that of the Biotechnology sector and 72.67% lower than that of the Health Care industry. The price to sales for all United States stocks is 135.51% lower than that of the firm.

Sellas Price To Sales Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Sellas Life's direct or indirect competition against its Price To Sales to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Sellas Life could also be used in its relative valuation, which is a method of valuing Sellas Life by comparing valuation metrics of similar companies.

Sellas Life is currently under evaluation in price to sales category among its peers.

Sellas Life Current Valuation Drivers

We derive many important indicators used in calculating different scores of Sellas Life from analyzing Sellas Life's financial statements. These drivers represent accounts that assess Sellas Life's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Sellas Life's important valuation drivers and their relationship over time.

	2020	2021	2022	2023	2024	2025 (projected)
Market Cap	46.3M	85.6M	45.8M	29.4M	33.9M	32.2M
Enterprise Value	12.0M	65.1M	29.6M	27.8M	32.0M	62.6M

Sellas Fundamentals

	Return On Equity	-5.35
	Return On Asset	-1.14
	Current Valuation	64.41 M
	Shares Outstanding	78.58 M
	Shares Owned By Insiders	0.16 %
	Shares Owned By Institutions	8.54 %
	Number Of Shares Shorted	8.65 M
	Price To Book	5.34 X
	Price To Sales	26.90 X
	Gross Profit	900 K
	EBITDA	529 K
	Net Income	(37.34 M)
	Cash And Equivalents	26.99 M
	Cash Per Share	1.31 X
	Total Debt	906 K
	Debt To Equity	0.06 %
	Current Ratio	2.36 X
	Book Value Per Share	0.25 X
	Cash Flow From Operations	(31.41 M)
	Short Ratio	2.90 X
	Earnings Per Share	(0.67) X
	Target Price	5.83
	Number Of Employees	16
	Beta	2.44
	Market Capitalization	95.08 M
	Total Asset	6.22 M
	Retained Earnings	(217.24 M)
	Working Capital	(10.56 M)
	Net Asset	6.22 M

About Sellas Life Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Sellas Life Sciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Sellas Life using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Sellas Life Sciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Sellas Stock Analysis

When running Sellas Life's price analysis, check to measure Sellas Life's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sellas Life is operating at the current time. Most of Sellas Life's value examination focuses on studying past and present price action to predict the probability of Sellas Life's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sellas Life's price. Additionally, you may evaluate how the addition of Sellas Life to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC